Adjuvant Chemo With S-1 Effective for Resected Pancreatic Cancer in Japanese Patients

Share this content:
Adjuvant chemotherapy with S-1 may improve care for Japanese patients with resected pancreatic cancer.
Adjuvant chemotherapy with S-1 may improve care for Japanese patients with resected pancreatic cancer.

For the treatment of resected pancreatic cancer, adjuvant chemotherapy with S-1--an oral drug related to 5-fluorouracil--significantly improves survival in Japanese patients, a study published in the journal The Lancet has shown.1

For the multicenter, open-label, phase 3 trial, investigators enrolled 377 patients with histologically proven invasive ductal carcinoma of the pancreas, pathologically documented stage I-III, with no local residual or microscopic residual tumor. Participants were randomly assigned 1:1 to receive gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle for up to 6 cycles, or S-1 at a dose of 40 mg, 50 mg, or 60 mg orally twice daily for 28 days on, 14 days off, of each 6-week cycle, for up to 4 cycles.

Results showed that S-1 reduced the risk of death by 43% (hazard ratio, 0.57; 95% CI, 0.44-0.72; Pnon-inferiority < .0001; P < .0001 for superiority) compared with gemcitabine. Five-year overall survival was 24.4% (95% CI, 18.6-30.8) with gemcitabine versus 44.1% (95% CI, 36.9-51.51) with S-1.

Researchers found that grade 3 to 4 leukoepenia, neutropenia, as well as increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were more frequently observed in the gemcitabine group, while stomatitis and diarrhea were common in the S-1 arm.

RELATED: FOLFIRINOX May Have Longer Median OS Than Gemcitabine for Pancreatic Cancer

The findings suggest that adjuvant chemotherapy with S-1 may be an improved standard of care for Japanese patients with resected pancreatic cancer. Future studies should be conducted to compare the efficacy and safety of these therapies in non-Asian patients.


1. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) [published online ahead of print June 2, 2016]. Lancet. doi: 10.1016/S0140-6736(16)30583-9.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs